, Volume 70, Issue 5, pp 513–528 | Cite as

Intravenous Immunoglobulins as a Treatment for Alzheimer’s Disease

Rationale and Current Evidence
  • Richard DodelEmail author
  • Frauke Neff
  • Carmen Noelker
  • Refik Pul
  • Yansheng Du
  • Michael Bacher
  • Wolfgang Oertel
Leading Article


Current treatment options for Alzheimer’s disease (AD) exert only a shortlived effect on disease symptoms. Active and passive immunotherapy have both been shown to be effective in clearing plaques, removing β-amyloid (Aβ) and improving behaviour in animal models of AD. Although the first active immunization trial in humans was discontinued because of severe adverse effects, several new approaches are currently being investigated in clinical trials. Recently, commercially available intravenous immunoglobulins (IVIG) have been used in small pilot trials for the treatment of patients with AD, based on the hypothesis that IVIG contains naturally occurring auto-antibodies (nAbs-Aβ) that specifically recognize and block the toxic effects of Ab. Furthermore, these nAbs-Aβ are reduced in AD patients compared with healthy controls, supporting the notion of replacement with IVIG. Beyond the occurrence of nAbs-Aβ, evidence for several other mechanisms associated with IVIG in AD has been reported in preclinical experiments and clinical studies. In 2009, a phase III clinical trial involving more than 360 AD patients was initiated and may provide conclusive evidence for the effect of IVIG as a treatment option for AD in 2011. In this article, we review the current knowledge and scientific rationale for using IVIG in patients with AD and other neurodegenerative disorders.


Amyloid Precursor Protein Piracetam IVIG Preparation IVIG Product Gammagard 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We thank Jennifer Manne for language editing. RD and MB hold patents on immunization in AD. RD and MB have received honoraria for presentations and research grants from several companies producing IVIG. The other authors have no conflicts of interest that are relevant to the content of this review. No sources of funding were used to assist in the preparation of this review.


  1. 1.
    Stangel M, Pul R. Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol 2006; 253 Suppl. 5: V18–24PubMedCrossRefGoogle Scholar
  2. 2.
    Gold R, Stangel M, Dalakas MC. Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 2007; 3(1): 36–44PubMedCrossRefGoogle Scholar
  3. 3.
    Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008; 15(9): 893–908PubMedCrossRefGoogle Scholar
  4. 4.
    Neff F, Wei X, Nolker C, et al. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev 2008; 7(6): 501–7PubMedCrossRefGoogle Scholar
  5. 5.
    Mandelkow E, von Bergen M, Biernat J, et al. Structural principles of tau and the paired helical filaments of Alzheimer’s disease. Brain Pathol 2007; 17(1): 83–90PubMedCrossRefGoogle Scholar
  6. 6.
    Hardy J. Has the amyloid cascade hypothesis for Alzheimer’s disease been proved? Curr Alzheimer Res 2006; 3(1): 71–3PubMedCrossRefGoogle Scholar
  7. 7.
    Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007; 69(16): 1622–34PubMedCrossRefGoogle Scholar
  8. 8.
    Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 2008; 31: 175–93PubMedCrossRefGoogle Scholar
  9. 9.
    Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400(6740): 173–7PubMedCrossRefGoogle Scholar
  10. 10.
    Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 2000; 408(6815): 982–5PubMedCrossRefGoogle Scholar
  11. 11.
    Roskam S, Neff F, Schwarting R, et al. APP transgenic mice: the effect of active and passive immunotherapy in cognitive tasks. Neurosci Biobehav Rev 2010; 34(4): 487–99PubMedCrossRefGoogle Scholar
  12. 12.
    Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005; 64(1): 94–101PubMedCrossRefGoogle Scholar
  13. 13.
    Schenk D. Amyloid-beta immunotherapy for Alzheimer’s disease: the end of the beginning. Nat Rev Neurosci 2002; 3(10): 824–8PubMedCrossRefGoogle Scholar
  14. 14.
    Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64(9): 1553–62PubMedCrossRefGoogle Scholar
  15. 15.
    Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372(9634): 216–23PubMedCrossRefGoogle Scholar
  16. 16.
    Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron 2003; 38(4): 547–54PubMedCrossRefGoogle Scholar
  17. 17.
    Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6(8): 916–9PubMedCrossRefGoogle Scholar
  18. 18.
    Das P, Howard V, Loosbrock N, et al. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/-knock-out mice. J Neurosci 2003; 23(24): 8532–8PubMedGoogle Scholar
  19. 19.
    Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9(4): 448–52PubMedCrossRefGoogle Scholar
  20. 20.
    Bacskai BJ, Kajdasz ST, Christie RH, et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001; 7(3): 369–72PubMedCrossRefGoogle Scholar
  21. 21.
    Taguchi H, Planque S, Nishiyama Y, et al. Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J Biol Chem 2008; 283(8): 4714–22PubMedCrossRefGoogle Scholar
  22. 22.
    DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 2001; 98(15): 8850–5PubMedCrossRefGoogle Scholar
  23. 23.
    Frenkel D, Maron R, Burt DS, et al. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest 2005; 115(9): 2423–33PubMedCrossRefGoogle Scholar
  24. 24.
    Solomon B. Antibody-mediated immunotherapy for Alzheimer’s disease. Curr Opin Investig Drugs 2007; 8(7): 519–24PubMedGoogle Scholar
  25. 25.
    Morgan C, Colombres M, Nunez MT, et al. Structure and function of amyloid in Alzheimer’s disease. Prog Neuro-biol 2004; 74(6): 323–49CrossRefGoogle Scholar
  26. 26.
    Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 2008; 14(8): 837–42PubMedCrossRefGoogle Scholar
  27. 27.
    Sarsoza F, Saing T, Kayed R, et al. A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol 2009; 118(4): 505–17PubMedCrossRefGoogle Scholar
  28. 28.
    Moretto N, Bolchi A, Rivetti C, et al. Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. J Biol Chem 2007; 282(15): 11436–45PubMedCrossRefGoogle Scholar
  29. 29.
    Petkova AT, Ishii Y, Balbach JJ, et al. A structural model for Alzheimer’s beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci U S A 2002; 99(26): 16742–7PubMedCrossRefGoogle Scholar
  30. 30.
    Pfeifer M, Boncristiano S, Bondolfi L, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002; 298(5597): 1379PubMedCrossRefGoogle Scholar
  31. 31.
    Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer’s disease model. Nat Neurosci 2002; 5(5): 452–7PubMedGoogle Scholar
  32. 32.
    O'Nuallain B, Acero L, Williams AD, et al. Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. Biochemistry 2008; 47(47): 12254–6PubMedCrossRefGoogle Scholar
  33. 33.
    Mohajeri MH, Gaugler MN, Martinez J, et al. Assessment of the bioactivity of antibodies against beta-amyloid peptide in vitro and in vivo. Neurodegener Dis 2004; 1(4–5): 160–7PubMedCrossRefGoogle Scholar
  34. 34.
    Wilcock DM, Rojiani A, Rosenthal A, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 2004; 24(27): 6144–51PubMedCrossRefGoogle Scholar
  35. 35.
    Kountouris D. Therapeutic effects of piracetam combined with intravenous immunoglobulin premature of Alzheimer type. J Neural Transm 2000; 107(5): 18Google Scholar
  36. 36.
    Dodel R, Du Y, Depboylu C, et al. Intravenous Immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2004; 75: 1472–4PubMedCrossRefGoogle Scholar
  37. 37.
    Relkin NR, Szabo P, Adamiak B, et al. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009; 30(11): 1328–36CrossRefGoogle Scholar
  38. 38.
    Relkin N, Tsakanikas DI, Adamiak B, et al. A double blind, placebo-controlled, phase II clinical trial of intravenous immunoglobulin (IVIG) for treatment of Alzheimer’s disease [abstract]. Neurology 2008; 70(11): A393Google Scholar
  39. 39.
    A phase 3 study evaluating safety and effectiveness of immune globulin intravenous (IGIV 10%) for the treatment of mild to moderate Alzheimer’s disease [ identifier NCT00818662]. US National Institutes of Health,, 2009 [online]. Available from URL: [Accessed 2010 Feb 10]
  40. 40.
    Study of Octagam 10% on the treatment of mild to moderate Alzheimer’s patients [ identifier NCT00812565]. US National Institutes of Health,, 2009 [online]. Available from URL: [Accessed 2010 Feb 10]
  41. 41.
    Du Y, Dodel R, Hampel H, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001; 57(5): 801–5PubMedCrossRefGoogle Scholar
  42. 42.
    Dodel R, Hampel H, Depboylu C, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer’s disease. Ann Neurol 2002; 52(2): 253–6PubMedCrossRefGoogle Scholar
  43. 43.
    Weksler ME, Relkin N, Turkenich R, et al. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 2002; 37(7): 943–8PubMedCrossRefGoogle Scholar
  44. 44.
    Shoenfeld Y, Gershwin ME, Meroni PL. Autoantibodies. Amsterdam: Elsevier, 2007Google Scholar
  45. 45.
    Fillit H, Hess G, Hill J, et al. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 2009; 73(3): 180–5PubMedCrossRefGoogle Scholar
  46. 46.
    Misra N, Bayry J, Ephrem A, et al. Intravenous immunoglobulin in neurological disorders: a mechanistic perspective. J Neurol 2005; 252 Suppl. 1: I1–6PubMedCrossRefGoogle Scholar
  47. 47.
    Hartung HP. Advances in the understanding of the mechanism of action of IVIg. J Neurol 2008; 255 Suppl. 3: 3–6PubMedCrossRefGoogle Scholar
  48. 48.
    Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345(10): 747–55PubMedCrossRefGoogle Scholar
  49. 49.
    Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513–33PubMedCrossRefGoogle Scholar
  50. 50.
    Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8(1): 34–47PubMedCrossRefGoogle Scholar
  51. 51.
    Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19: 275–90PubMedCrossRefGoogle Scholar
  52. 52.
    Bruhns P, Samuelsson A, Pollard JW, et al. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 2003; 18(4): 573–81PubMedCrossRefGoogle Scholar
  53. 53.
    Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291(5503): 484–6PubMedCrossRefGoogle Scholar
  54. 54.
    Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001; 98(4): 1095–9PubMedCrossRefGoogle Scholar
  55. 55.
    Siragam V, Crow AR, Brinc D, et al. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 2006; 12(6): 688–92PubMedCrossRefGoogle Scholar
  56. 56.
    Bazin R, Lemieux R, Tremblay T. Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody. Br J Haematol 2006; 135(1): 97–100PubMedCrossRefGoogle Scholar
  57. 57.
    Akilesh S, Petkova S, Sproule TJ, et al. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest 2004; 113(9): 1328–33PubMedGoogle Scholar
  58. 58.
    Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313(5787): 670–3PubMedCrossRefGoogle Scholar
  59. 59.
    Anthony RM, Wermeling F, Karlsson MC, et al. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A 2008; 105(50): 19571–8PubMedCrossRefGoogle Scholar
  60. 60.
    Konrad S, Baumann U, Schmidt RE, et al. Intravenous immunoglobulin (IVIG)-mediated neutralisation of C5a: a direct mechanism of IVIG in the maintenance of a high Fc gammaRIIB to Fc gammaRIII expression ratio on macrophages. Br J Haematol 2006; 134(3): 345–7PubMedCrossRefGoogle Scholar
  61. 61.
    Frank MM, Basta M, Fries LF. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 1992; 62 (1 Pt 2): S82–6PubMedCrossRefGoogle Scholar
  62. 62.
    Mollnes TE, Hogasen K, De Carolis C, et al. High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol 1998; 48(3): 312–7PubMedCrossRefGoogle Scholar
  63. 63.
    Lutz HU, Stammler P, Jelezarova E, et al. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996; 88(1): 184–93PubMedGoogle Scholar
  64. 64.
    Basta M, Van Goor F, Luccioli S, et al. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003; 9(4): 431–8PubMedCrossRefGoogle Scholar
  65. 65.
    Rissmann A, Pieper S, Adams I, et al. Increased blood plasma concentrations of TGF-beta1 and TGF-beta2 after treatment with intravenous immunoglobulins in childhood autoimmune diseases. Pediatr Allergy Immunol 2009; 20(3): 261–5PubMedCrossRefGoogle Scholar
  66. 66.
    Stangel M, Schumacher HC, Ruprecht K, et al. Immunoglobulins for intravenous use inhibit TNF alpha cytotoxicity in vitro. Immunol Invest 1997; 26(5-7): 569–78PubMedCrossRefGoogle Scholar
  67. 67.
    Wu KH, Wu WM, Lu MY, et al. Inhibitory effect of pooled human immunoglobulin on cytokine production in peripheral blood mononuclear cells. Pediatr Allergy Immunol 2006; 17(1): 60–8PubMedCrossRefGoogle Scholar
  68. 68.
    Ghio M, Contini P, Negrini S, et al. sHLA-I contaminating molecules as novel mechanism of ex vivo/in vitro transcriptional and posttranscriptional modulation of transforming growth factor-beta in CD8+ T lymphocytes and neutrophils after intravenous immunoglobulin treatment. Transfusion. Epub 2009 Nov 9Google Scholar
  69. 69.
    Kekow J, Reinhold D, Pap T, et al. Intravenous immunoglobulins and transforming growth factor beta. Lancet 1998; 351(9097): 184–5PubMedCrossRefGoogle Scholar
  70. 70.
    Park-Min KH, Serbina NV, Yang W, et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 2007; 26(1): 67–78PubMedCrossRefGoogle Scholar
  71. 71.
    Gaskin F, Finley J, Fang Q, et al. Human antibodies reactive with beta-amyloid protein in Alzheimer’s disease. J Exp Med 1993; 177(4): 1181–6PubMedCrossRefGoogle Scholar
  72. 72.
    Gaskin F, Kingsley BS, Fu SM. Autoantibodies to neuro-fibrillary tangles and brain tissue in Alzheimer’s disease. Establishment of Epstein-Barr virus-transformed antibody-producing cell lines. J Exp Med 1987; 165(1): 245–50Google Scholar
  73. 73.
    Du Y, Wei X, Dodel R, et al. Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 2003; 126 (Pt 9): 1935–9PubMedCrossRefGoogle Scholar
  74. 74.
    Xu S, Gaskin F. Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer’s disease. Mech Ageing Dev 1997; 94(1–3): 213–22PubMedCrossRefGoogle Scholar
  75. 75.
    Geylis V, Kourilov V, Meiner Z, et al. Human monoclonal antibodies against amyloid-beta from healthy adults. Neurobiol Aging 2005; 26(5): 597–606PubMedCrossRefGoogle Scholar
  76. 76.
    Istrin G, Bosis E, Solomon B. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J Neurosci Res 2006; 84(2): 434–43PubMedCrossRefGoogle Scholar
  77. 77.
    Schaffer C, Blanché-Ganter E. Qualität polyvalenter Immunglobuline. Krankenhauspharmazie 1998; 19: 280–6Google Scholar
  78. 78.
    Pul R, Nguyen D, Schmitz U, et al. Comparison of intravenous immunoglobulin preparations on microglial function in vitro: more potent immunomodulatory capacity of an IgM/IgA-enriched preparation. Clin Neuropharmacol 2002; 25(5): 254–9PubMedCrossRefGoogle Scholar
  79. 79.
    Kellner A, Matschke J, Bernreuther C, et al. Autoantibodies against beta-amyloid are common in Alzheimer’s disease and help control plaque burden. Ann Neurol 2009; 65(1): 24–31PubMedCrossRefGoogle Scholar
  80. 80.
    Tampellini D, Magrane J, Takahashi RH, et al. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J Biol Chem 2007; 282(26): 18895–906PubMedCrossRefGoogle Scholar
  81. 81.
    Moir RD, Tseitlin KA, Soscia S, et al. Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer’s disease patients. J Biol Chem 2005; 280(17): 17458–63PubMedCrossRefGoogle Scholar
  82. 82.
    Song MS, Mook-Jung I, Lee HJ, et al. Serum anti-amyloid-beta antibodies and Alzheimer’s disease in elderly Korean patients. J Int Med Res 2007; 35(3): 301–6PubMedGoogle Scholar
  83. 83.
    Sohn JH, So JO, Hong HJ, et al. Identification of auto-antibody against beta-amyloid peptide in the serum of elderly. Front Biosci 2009; 14: 3879–83PubMedCrossRefGoogle Scholar
  84. 84.
    Jianping L, Zhibing Y, Wei Q, et al. Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease. Alzheimer Dis Assoc Disord 2006; 20(3): 127–32PubMedCrossRefGoogle Scholar
  85. 85.
    Brettschneider S, Morgenthaler NG, Teipel SJ, et al. Decreased serum amyloid beta(1–42) autoantibody levels in Alzheimer’s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1–42) peptide. Biol Psychiatry 2005; 57(7): 813–6PubMedCrossRefGoogle Scholar
  86. 86.
    Hansson SF, Andreasson U, Wall M, et al. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer’s disease patients. J Alzheimers Dis 2009; 16(2): 389–97PubMedGoogle Scholar
  87. 87.
    Nath A, Hall E, Tuzova M, et al. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer’s disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolec Med 2003; 3(1): 29–39CrossRefGoogle Scholar
  88. 88.
    Gruden MA, Davudova TB, Malisauskas M, et al. Autoimmune responses to amyloid structures of Abeta(25–35) peptide and human lysozyme in the serum of patients with progressive Alzheimer’s disease. Dement Geriatr Cogn Disord 2004; 18(2): 165–71PubMedCrossRefGoogle Scholar
  89. 89.
    Mruthinti S, Buccafusco JJ, Hill WD, et al. Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging 2004; 25(8): 1023–32PubMedCrossRefGoogle Scholar
  90. 90.
    Hyman BT, Smith C, Buldyrev I, et al. Autoantibodies to amyloid-beta and Alzheimer’s disease. Ann Neurol 2001; 49(6): 808–10PubMedCrossRefGoogle Scholar
  91. 91.
    Baril L, Nicolas L, Croisile B, et al. Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer’s disease and control subjects. Neurosci Lett 2004; 355(3): 226–30PubMedCrossRefGoogle Scholar
  92. 92.
    Weber A, Engelmaier A, Teschner H, et al. Intravenous immunoglobulin (IVIG) Gammagard Liquid contains anti-RAGE IGG and SLRP. ICAD Abstract 2009; P3: 43Google Scholar
  93. 93.
    Dalakas MC, Späth PJ. Intravenous immunoglobulins in the third millennium. New York: Parthenon Publishing Group, 2004Google Scholar
  94. 94.
    Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002; 59 (12 Suppl. 6): S13–21PubMedCrossRefGoogle Scholar
  95. 95.
    Quan Y, Moller T, Weinstein JR. Regulation of Fcgamma receptors and immunoglobulin G-mediated phagocytosis in mouse microglia. Neurosci Lett 2009; 464(1): 29–33PubMedCrossRefGoogle Scholar
  96. 96.
    Sewell WA, North ME, Cambronero R, et al. In vivo modulation of cytokine synthesis by intravenous immunoglobulin. Clin Exp Immunol 1999; 116(3): 509–15PubMedCrossRefGoogle Scholar
  97. 97.
    World Health Organization. Appropriate uses of human immunoglobulin in clinical practice: memorandum from an IUIS/WHO meeting. WHO Bulletin 1982; 60: 43–7Google Scholar
  98. 98.
    International patient organisation for primary immunodeficiencies. IVIG preparations currently available. 2009 [online]. Available from URL: [Accessed 2010 Feb 10]
  99. 99.
    Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006; 6(4): 592–9PubMedCrossRefGoogle Scholar
  100. 100.
    Martin TD. IGIV: contents, properties, and methods of industrial production-evolving closer to a more physiologic product. Int Immunopharmacol 2006; 6(4): 517–22PubMedCrossRefGoogle Scholar
  101. 101.
    Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm 2005; 62 (16 Suppl. 3): S5–11PubMedCrossRefGoogle Scholar
  102. 102.
    Relkin NR, Szabo P, Rotondi M, et al. Antibodies in the dimer fraction of IVIG have the capacity to bind beta amyloid. ICAD Abstract 2009: 43Google Scholar
  103. 103.
    Safavi A. Comparison of several human immunoglobulin products for anti-Aβ 1–42 titer [abstract]. Alzheimer’s Dementia 2006; 2 (3 Suppl. 1): S591CrossRefGoogle Scholar
  104. 104.
    Balakrishnan K, Andrei-Selmer L, Selmer T, et al. Comparison of intravenous immunoglobulins for naturally occurring antibodies against β-amyloid. J Alzheimers Dis. In pressGoogle Scholar
  105. 105.
    Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006; 6(4): 535–42PubMedCrossRefGoogle Scholar
  106. 106.
    Katz U, Achiron A, Sherer Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007; 6(4): 257–9PubMedCrossRefGoogle Scholar
  107. 107.
    Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007; 38(1-3): 122–32PubMedCrossRefGoogle Scholar
  108. 108.
    Stangel M, Kiefer R, Pette M, et al. Side effects of intravenous immunoglobulins in neurological autoimmune disorders—a prospective study. J Neurol 2003; 250(7): 818–21PubMedCrossRefGoogle Scholar
  109. 109.
    Brannagan 3rd TH, Nagle KJ, Lange DJ, et al. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996; 47(3): 674–7PubMedCrossRefGoogle Scholar
  110. 110.
    Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol 2003; 50(3): 172–5PubMedCrossRefGoogle Scholar
  111. 111.
    Papachroni KK, Ninkina N, Papapanagiotou A, et al. Autoantibodies to alpha-synuclein in inherited Parkinson’s disease. J Neurochem 2007; 101(3): 749–56PubMedCrossRefGoogle Scholar
  112. 112.
    Shankle WR. Longitudinal measure of IVIG treatment effect in patients with Alzheimer’s and Lewy body disease. ICAD Abstract 2009; P3: 43Google Scholar
  113. 113.
    Rosenmann H, Meiner Z, Geylis V, et al. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer’s disease and healthy subjects. Neurosci Lett 2006; 410(2): 90–3PubMedCrossRefGoogle Scholar
  114. 114.
    Wei X, He Y, Tan J, et al. Human anti-prion protein antibodies block A117V PrProtein fibril formation and prevent A117V prion protein peptide-induced neurotoxicity. Eur Psychiatry 2008; 23: S39–SCrossRefGoogle Scholar
  115. 115.
    Bayry J, Kazatchkine MD, Kaveri SV. Shortage of human intravenous immunoglobulin-reasons and possible solutions. Nat Clin Pract Neurol 2007; 3(3): 120–1PubMedCrossRefGoogle Scholar
  116. 116.
    Boulis A, Goold S, Ubel PA. Responding to the immunoglobulin shortage: a case study. J Health Polit Policy Law 2002; 27(6): 977–99PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Richard Dodel
    • 1
    Email author
  • Frauke Neff
    • 1
  • Carmen Noelker
    • 1
  • Refik Pul
    • 2
  • Yansheng Du
    • 3
  • Michael Bacher
    • 1
  • Wolfgang Oertel
    • 1
  1. 1.Department of NeurologyPhilipps-University MarburgMarburgGermany
  2. 2.Department of NeurologyHannover Medical SchoolHannoverGermany
  3. 3.Department of NeurologyIndiana UniversityIndianapolisUSA

Personalised recommendations